{"id":333596,"date":"2026-10-30T15:03:24","date_gmt":"2026-10-30T09:33:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=333596"},"modified":"2026-10-30T15:03:24","modified_gmt":"2026-10-30T09:33:24","slug":"high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/","title":{"rendered":"3 High Volume Diagnostics Laboratory, Multi Speciality Hospitals Operator and Biopharma Technology Services Firm Stocks With a Strong Future Roadmap: Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene: ROE of 11.4% to 27.9% and FY22 to FY26 revenue CAGR of 8.2% to 20.7%. Prices as of 29 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three lab, hospital and pharma services stocks to watch are Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene. Their return on equity ranges from 11.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 20.7%. Thyrocare Technologies has the highest return on equity at 27.9%, while Indegene has the fastest revenue growth at 20.7% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Lab, hospital and pharma services stocks offer a focused view of a sector where demand keeps widening. Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene cover a high volume diagnostics laboratory, a multi speciality hospitals operator and a biopharma technology services firm.<\/p>\n<p>This list covers three lab, hospital and pharma services stocks with complete current figures: Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#What_Are_Lab_Hospital_and_Pharma_Services_Stocks\" title=\"What Are Lab, Hospital and Pharma Services Stocks?\">What Are Lab, Hospital and Pharma Services Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Lab_Hospital_and_Pharma_Services_Stocks_at_a_Glance\" title=\"Lab, Hospital and Pharma Services Stocks at a Glance\">Lab, Hospital and Pharma Services Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Why_Do_Lab_Hospital_and_Pharma_Services_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Lab, Hospital and Pharma Services Stocks Have a Strong Roadmap in India?\">Why Do Lab, Hospital and Pharma Services Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Why_Thyrocare_Technologies_Features_Among_These_Lab_Hospital_and_Pharma_Services_Stocks\" title=\"Why Thyrocare Technologies Features Among These Lab, Hospital and Pharma Services Stocks\">Why Thyrocare Technologies Features Among These Lab, Hospital and Pharma Services Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Why_Jupiter_Life_Line_Hospitals_Features_Among_These_Lab_Hospital_and_Pharma_Services_Stocks\" title=\"Why Jupiter Life Line Hospitals Features Among These Lab, Hospital and Pharma Services Stocks\">Why Jupiter Life Line Hospitals Features Among These Lab, Hospital and Pharma Services Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Why_Indegene_Features_Among_These_Lab_Hospital_and_Pharma_Services_Stocks\" title=\"Why Indegene Features Among These Lab, Hospital and Pharma Services Stocks\">Why Indegene Features Among These Lab, Hospital and Pharma Services Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Thyrocare_Technologies_vs_Jupiter_Life_Line_Hospitals_vs_Indegene_on_Key_Financials\" title=\"Thyrocare Technologies vs Jupiter Life Line Hospitals vs Indegene on Key Financials\">Thyrocare Technologies vs Jupiter Life Line Hospitals vs Indegene on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Key_Risks_to_Check_Before_Investing_in_Lab_Hospital_and_Pharma_Services_Stocks\" title=\"Key Risks to Check Before Investing in Lab, Hospital and Pharma Services Stocks\">Key Risks to Check Before Investing in Lab, Hospital and Pharma Services Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Final_Thoughts_on_Lab_Hospital_and_Pharma_Services_Stocks\" title=\"Final Thoughts on Lab, Hospital and Pharma Services Stocks\">Final Thoughts on Lab, Hospital and Pharma Services Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#What_are_lab_hospital_and_pharma_services_stocks\" title=\"What are lab, hospital and pharma services stocks?\">What are lab, hospital and pharma services stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Which_lab_hospital_and_pharma_services_stocks_are_covered_in_this_list\" title=\"Which lab, hospital and pharma services stocks are covered in this list?\">Which lab, hospital and pharma services stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Why_do_lab_hospital_and_pharma_services_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do lab, hospital and pharma services stocks have a strong future roadmap in India?\">Why do lab, hospital and pharma services stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#How_has_Thyrocare_Technologies_performed_financially\" title=\"How has Thyrocare Technologies performed financially?\">How has Thyrocare Technologies performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#How_has_Jupiter_Life_Line_Hospitals_performed_financially\" title=\"How has Jupiter Life Line Hospitals performed financially?\">How has Jupiter Life Line Hospitals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#How_has_Indegene_performed_financially\" title=\"How has Indegene performed financially?\">How has Indegene performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#What_risks_should_investors_check_before_buying_lab_hospital_and_pharma_services_stocks\" title=\"What risks should investors check before buying lab, hospital and pharma services stocks?\">What risks should investors check before buying lab, hospital and pharma services stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and-biopharma-technology-services-firm-stocks-roadmap-trailmap-list\/#Is_this_list_of_lab_hospital_and_pharma_services_stocks_investment_advice\" title=\"Is this list of lab, hospital and pharma services stocks investment advice?\">Is this list of lab, hospital and pharma services stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Lab_Hospital_and_Pharma_Services_Stocks\"><\/span><strong>What Are Lab, Hospital and Pharma Services Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lab, hospital and pharma services stocks are listed companies that run a central testing laboratory with a wide partner network, operate hospitals with strong maternity, child care and surgery services and help drug and device makers with commercial, medical and regulatory work. Their earnings depend on test volumes, patient numbers and client contracts.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Lab_Hospital_and_Pharma_Services_Stocks_at_a_Glance\"><\/span><strong>Lab, Hospital and Pharma Services Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/thyrocare\/thyrocare-technologies-ltd-share-price-today\">Thyrocare Technologies<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">515.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,501<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">42.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.09<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/jlhl\/jupiter-life-line-hospitals-ltd-share-price-today\">Jupiter Life Line Hospitals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">260.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,007<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">42.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">58.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.41<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/indgn\/indegene-ltd-share-price-today\">Indegene<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">593.45<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,454<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing lab, hospital and pharma services stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Lab_Hospital_and_Pharma_Services_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Lab, Hospital and Pharma Services Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lab, hospital and pharma services stocks have a strong roadmap in India because rising health awareness, wider screening and insurance cover and growing use of data in drug development keep widening the market for these healthcare companies.<\/p>\n<ul>\n<li><strong>Preventive care.<\/strong> More people take regular health tests.<\/li>\n<li><strong>Hospital demand.<\/strong> Families seek trusted maternity and surgical care.<\/li>\n<li><strong>Pharma services.<\/strong> Drug makers outsource commercial work.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Thyrocare_Technologies_Features_Among_These_Lab_Hospital_and_Pharma_Services_Stocks\"><\/span><strong>Why Thyrocare Technologies Features Among These Lab, Hospital and Pharma Services Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the lab, hospital and pharma services stocks on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.<\/p>\n<p>The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.<\/p>\n<p><strong>What to watch:<\/strong> Track growth in test volume per day and the share of revenue from preventive health packages.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Jupiter_Life_Line_Hospitals_Features_Among_These_Lab_Hospital_and_Pharma_Services_Stocks\"><\/span><strong>Why Jupiter Life Line Hospitals Features Among These Lab, Hospital and Pharma Services Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the patient care and life science shares on this list, Jupiter Life Line Hospitals runs multi-speciality hospitals in Pune, Thane and Indore, with strong services in maternity, child care, critical care and advanced surgery.<\/p>\n<p>Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%.<\/p>\n<p>The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 58.4.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.<\/p>\n<p><strong>What to watch:<\/strong> Follow bed additions, occupancy levels and revenue per occupied bed.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Indegene_Features_Among_These_Lab_Hospital_and_Pharma_Services_Stocks\"><\/span><strong>Why Indegene Features Among These Lab, Hospital and Pharma Services Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Indegene is a Bengaluru-based healthcare technology and services company that helps biopharma and medical technology firms with commercial, medical and regulatory work using data and technology.<\/p>\n<p>In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%.<\/p>\n<p>Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 59.2.<\/p>\n<p><strong>Roadmap:<\/strong> The company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.<\/p>\n<p><strong>What to watch:<\/strong> Monitor client additions, platform adoption and growth in artificial intelligence services.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Thyrocare_Technologies_vs_Jupiter_Life_Line_Hospitals_vs_Indegene_on_Key_Financials\"><\/span><strong>Thyrocare Technologies vs Jupiter Life Line Hospitals vs Indegene on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three lab, hospital and pharma services stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Thyrocare Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">618<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">846<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">163<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Jupiter Life Line Hospitals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">737<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,542<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">194<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Indegene<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,690<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,582<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">401<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Indegene combines the largest FY26 revenue at Rs 3,582 crore with the fastest revenue growth, a 20.7% compound annual rate. A useful habit with lab, hospital and pharma services stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Lab_Hospital_and_Pharma_Services_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Lab, Hospital and Pharma Services Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these lab, hospital and pharma services stocks, the main points are: Long-term patient care and life science shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Test volumes.<\/strong> Footfall and test mix can vary with seasons.<\/li>\n<li><strong>Capacity ramp up.<\/strong> New hospitals take time to fill beds and reach full returns.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter lab, hospital and pharma services stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Lab_Hospital_and_Pharma_Services_Stocks\"><\/span><strong>Final Thoughts on Lab, Hospital and Pharma Services Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lab, hospital and pharma services stocks reward patient research into demand, execution and financial strength. Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene each have a clear plan to grow. Based on the 29 October 2026 close, Thyrocare Technologies trades at Rs 515.5, Jupiter Life Line Hospitals at Rs 260.1 and Indegene at Rs 593.45. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these lab, hospital and pharma services stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track lab, hospital and pharma services stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_lab_hospital_and_pharma_services_stocks\"><\/span><strong>What are lab, hospital and pharma services stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lab, hospital and pharma services stocks are listed companies that run a central testing laboratory with a wide partner network, operate hospitals with strong maternity, child care and surgery services and help drug and device makers with commercial, medical and regulatory work. Their earnings depend on test volumes, patient numbers and client contracts. This list looks at three of them, Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_lab_hospital_and_pharma_services_stocks_are_covered_in_this_list\"><\/span><strong>Which lab, hospital and pharma services stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene. Based on the 29 October 2026 close, Thyrocare Technologies traded at Rs 515.5, Jupiter Life Line Hospitals at Rs 260.1 and Indegene at Rs 593.45. Their return on equity ranges from 11.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 20.7%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_lab_hospital_and_pharma_services_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do lab, hospital and pharma services stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lab, hospital and pharma services stocks have a strong roadmap in India because rising health awareness, wider screening and insurance cover and growing use of data in drug development keep widening the market for these healthcare companies. The main drivers are as follows. Preventive care. More people take regular health tests. Hospital demand. Families seek trusted maternity and surgical care. Pharma services. Drug makers outsource commercial work. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Thyrocare_Technologies_performed_financially\"><\/span><strong>How has Thyrocare Technologies performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Jupiter_Life_Line_Hospitals_performed_financially\"><\/span><strong>How has Jupiter Life Line Hospitals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 58.4. Looking ahead, the company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Indegene_performed_financially\"><\/span><strong>How has Indegene performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 59.2. Looking ahead, the company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_lab_hospital_and_pharma_services_stocks\"><\/span><strong>What risks should investors check before buying lab, hospital and pharma services stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying lab, hospital and pharma services stocks. Test volumes. Footfall and test mix can vary with seasons. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_lab_hospital_and_pharma_services_stocks_investment_advice\"><\/span><strong>Is this list of lab, hospital and pharma services stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are lab, hospital and pharma services stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lab, hospital and pharma services stocks are listed companies that run a central testing laboratory with a wide partner network, operate hospitals with strong maternity, child care and surgery services and help drug and device makers with commercial, medical and regulatory work. Their earnings depend on test volumes, patient numbers and client contracts. This list looks at three of them, Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which lab, hospital and pharma services stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene. Based on the 29 October 2026 close, Thyrocare Technologies traded at Rs 515.5, Jupiter Life Line Hospitals at Rs 260.1 and Indegene at Rs 593.45. Their return on equity ranges from 11.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 20.7%.\"}},{\"@type\":\"Question\",\"name\":\"Why do lab, hospital and pharma services stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lab, hospital and pharma services stocks have a strong roadmap in India because rising health awareness, wider screening and insurance cover and growing use of data in drug development keep widening the market for these healthcare companies. The main drivers are as follows. Preventive care. More people take regular health tests. Hospital demand. Families seek trusted maternity and surgical care. Pharma services. Drug makers outsource commercial work. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Thyrocare Technologies performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.\"}},{\"@type\":\"Question\",\"name\":\"How has Jupiter Life Line Hospitals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P\/E of 42.6, below the industry P\/E of 58.4. Looking ahead, the company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.\"}},{\"@type\":\"Question\",\"name\":\"How has Indegene performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P\/E of 36.0, below the industry P\/E of 59.2. Looking ahead, the company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying lab, hospital and pharma services stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying lab, hospital and pharma services stocks. Test volumes. Footfall and test mix can vary with seasons. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of lab, hospital and pharma services stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lab, Hospital and Pharma Services Stocks with a strong future roadmap: Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.<\/p>\n","protected":false},"author":36,"featured_media":333595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,18671,11217,15757,18670,18673,18672,9126],"class_list":["post-333596","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-hospital-and-pharma-services-stocks","tag-indegene","tag-jupiter-life-line-hospitals","tag-lab","tag-lab-and-hospital-stocks","tag-patient-care-and-life-science-shares","tag-thyrocare-technologies"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["333595"],"rank_math_title":["Diagnostics Lab, Hospital and Pharma Services Stocks"],"rank_math_description":["Compare 3 lab, hospital and pharma services stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 28 Oct 2026."],"rank_math_focus_keyword":["lab, hospital and pharma services stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-high-volume-diagnostics-laboratory-multi-speciality-hospitals-operator-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=333596"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333596\/revisions"}],"predecessor-version":[{"id":333597,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333596\/revisions\/333597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/333595"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=333596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=333596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=333596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}